What is quantum computing and how is it different from classical computing?

Classical computers store and process information as bits — each one is either a 0 or a 1 at any given moment. Quantum computers use quantum bits (qubits), which exploit two quantum mechanical phenomena to work differently. Superposition allows a qubit to represent 0 and 1 simultaneously until measured — not as a 50/50 probability, but as a genuine quantum state that contains both simultaneously. Entanglement links two or more qubits so that the state of one instantaneously determines the state of the other, regardless of physical separation, creating correlated computation across the system. Together, these properties allow a quantum computer of N qubits to explore 2^N states simultaneously in certain types of computation. This does not mean quantum computers are universally faster — they are only faster for specific problem classes where quantum algorithms provide an advantage. For most everyday computing tasks (running a spreadsheet, rendering video, processing text), classical computers are equivalent or faster. Quantum advantage exists for problems involving enormous combinatorial search spaces, quantum system simulation, certain optimisation problems, and some cryptographic applications — which is why drug discovery and molecular simulation are among the highest-priority healthcare applications.

Is quantum computing being used in healthcare today?

Yes, but in limited and largely experimental ways. As of 2026, several pharmaceutical companies (including Roche, AstraZeneca, Boehringer Ingelheim, and Merck) have active quantum computing partnerships with IBM, Google, and specialised quantum hardware companies. These are primarily proof-of-concept projects demonstrating quantum approaches to molecular simulation, drug-protein binding affinity calculations, and combinatorial chemistry optimisation — they are not yet replacing classical computational pipelines in production drug discovery. D-Wave's quantum annealing systems have been tested for hospital scheduling optimisation problems. A small number of medical imaging studies have tested quantum-enhanced machine learning algorithms for MRI reconstruction and anomaly detection. The honest characterisation of 2026 is: quantum hardware has crossed important thresholds (Google's 2023 'beyond classical' demonstration on a specific task, IBM's 1000+ qubit Condor processor, error correction demonstrations), but error rates remain too high for the fault-tolerant computation that most high-value healthcare applications require. The current NISQ (Noisy Intermediate-Scale Quantum) era is a transitional period between experimental demonstration and practical application.

When will quantum computers be able to simulate drug molecules accurately?

The specific quantum advantage target for drug discovery is accurate simulation of electron correlation in molecules larger than 50–100 atoms — the point where classical methods (density functional theory, coupled cluster) become computationally intractable. Resource estimates from IBM, Google, and academic groups suggest this will require fault-tolerant quantum computers with roughly 1–4 million physical qubits at below 0.1% error rates per gate operation. Current leaders (IBM Condor at 1121 qubits, Google Willow at 105 qubits but with lower error rates) are 2–3 orders of magnitude short of this target on both qubit count and error rates simultaneously. Realistic timelines from the research community cluster around 2030–2035 for early fault-tolerant quantum advantage in small drug-relevant molecule simulation, and 2035–2040 for the larger molecular systems that represent full industrialisation of quantum-assisted drug discovery. Timelines have historically been optimistic in this field — the 2026 estimate from the most sober analyses suggests meaningful clinical impact from quantum drug discovery is more likely in the 2035–2045 window than the 2028–2032 window that was common in announcements circa 2020–2022.

How does quantum computing relate to AI and machine learning in healthcare?

Quantum computing and AI are distinct technologies that intersect in a specific way relevant to healthcare. Classical AI (the neural networks and large language models behind tools like medical imaging analysis, clinical decision support, and genomic risk prediction) runs on classical hardware and does not require quantum computing to function or improve. Quantum machine learning (QML) refers to quantum algorithms for certain ML tasks — primarily training quantum neural networks on quantum hardware or applying quantum-enhanced kernel methods. Most QML algorithms proposed to date have not demonstrated a clear quantum advantage over optimised classical ML, and some theoretical results suggest the advantage may be limited. The most credible quantum-AI intersection in healthcare is using quantum computers as simulators for quantum systems (molecular dynamics, protein folding energetics) to generate training data or calculate properties that are impossible to obtain classically — then feeding these results into classical AI models. IBM's Qiskit and Google's TensorFlow Quantum frameworks enable hybrid classical-quantum computation of this type. The scenario where quantum computers directly run the AI models powering clinical decision support is considerably further out than the hybrid approach.

What is the difference between quantum computing and quantum medicine?

Quantum computing and quantum medicine are related in their branding but distinct in their substance. Quantum computing is a precisely defined engineering discipline: building processors that exploit quantum mechanical phenomena (superposition, entanglement, quantum tunnelling) to perform certain computations faster than classical machines. Its relationship to healthcare is instrumental — it is a tool that could accelerate drug discovery, genomic analysis, and molecular simulation. Quantum medicine, as QuanMed AI uses the term, refers to a broader framework for understanding human biology through the lens of quantum biophysics — the quantum mechanical phenomena that occur naturally in biological systems. This includes the quantum coherence effects demonstrated in photosynthetic energy transfer, the quantum tunnelling that enables enzyme-catalysed reactions at rates impossible by classical chemistry, the radical pair mechanism behind avian magnetoreception and potentially human magnetosensing, and the role of electron tunnelling in mitochondrial oxidative phosphorylation. These are not speculative — they are established biophysics. The frontier question is how far quantum effects propagate into macroscopic biological function and how disrupting them (through artificial light, toxic exposure, electromagnetic pollution) degrades health outcomes. Quantum computing is the computational tool; quantum medicine is the biological framework.

What should healthcare professionals know about quantum computing now?

Healthcare professionals do not need to become quantum physicists, but the following orientation is practically useful. First: quantum computing will matter for pharmaceutical pipelines before it matters for clinical practice — the earliest impact will be in the drug discovery and development phase, not in bedside tools or diagnostic equipment. Second: the 5–10 year timeline often cited in press releases for 'quantum healthcare revolution' is optimistic; credible impact on drug discovery is more likely in the 2033–2040 window. Third: the most actionable near-term application is quantum-inspired optimisation (classical algorithms designed to mimic quantum approaches) for hospital operations, scheduling, and logistics — these are deployable now on classical hardware and several hospitals have implemented them. Fourth: the intersection of quantum computing with genomics is real and near-term: quantum algorithms for genome assembly, haplotype phasing, and variant calling have demonstrated speedups over classical methods on current hardware. Fifth: the talent ecosystem is developing rapidly — understanding the landscape of quantum-enabled drug pipelines will become relevant for evaluating pharmaceutical research quality in the mid-2030s, much as understanding statistical methods became essential for evaluating clinical trials. Following IBM's and Google's annual quantum roadmap updates is sufficient to stay current without deep technical immersion.

Quantum Computing in Healthcare: Timeline & Reality Check (2026)

Summary

Quantum computing will transform drug discovery, protein simulation, and genomics — but the timeline is longer than the press releases suggest. Now (2026): proof-of-concept pharmaceutical partnerships, quantum-inspired classical optimisation in hospital logistics, early genomic speedups. 2028–2032: first fault-tolerant quantum advantage on small molecules, hybrid quantum-classical drug pipelines in production, quantum genomics for rare disease. 2033–2040: industrialised quantum-assisted drug discovery for large molecules, quantum advantage in protein-ligand binding prediction, potential impact on personalised medicine. The barrier is hardware: current NISQ-era machines have too many errors for the most valuable applications.

Why Quantum Computing Matters for Medicine

The molecular machinery of biology is quantum mechanical. Every enzymatic reaction, every electron transfer in the mitochondrial respiratory chain, every protein fold is governed by quantum mechanics at its foundation. Classical computers simulate these processes using approximations — approximations that become increasingly inadequate as molecules grow larger and more complex. This is not a hardware limitation that faster classical processors will eventually overcome: it is a fundamental mathematical constraint. The computational cost of exactly simulating the quantum state of N electrons scales exponentially with N on a classical computer. For a small drug molecule with 50 electrons, exact classical simulation is already at the edge of what is tractable. For a protein active site with 200+ electrons interacting with a drug candidate, exact classical simulation is simply impossible at any foreseeable scale of classical hardware.

Quantum computers are not limited by this exponential wall for quantum simulation tasks because they are themselves quantum mechanical devices. A quantum computer of sufficient size and quality could, in principle, exactly simulate the quantum state of a molecule using resources that scale polynomially rather than exponentially with system size. This is the fundamental insight from Richard Feynman's 1982 proposal that launched the field: the best simulator of a quantum system is another quantum system. For healthcare, this means quantum computers could eventually compute drug-target binding affinities, protein folding energetics, and metabolic reaction rates with a precision impossible by any classical method — transforming drug discovery from trial-and-error empiricism into genuine computational design.

That potential is real and not seriously disputed by physicists or computer scientists. The disputed question is timeline: when will quantum hardware reach the quality needed to deliver this advantage in practice? The honest answer, drawing on the most credible technical assessments from IBM, Google, Microsoft, academic quantum computing groups, and independent analysts, is: not yet, and not imminently — but the trajectory is measurable and progress is genuine. This article maps that trajectory with as much precision as current evidence allows.

The State of Quantum Hardware in 2026

Understanding where quantum hardware stands requires three numbers: qubit count, gate error rate, and qubit connectivity. All three matter, and qubit count alone — the metric most emphasised in press releases — is the least informative of the three.

Company / System	Architecture	Qubits (2026)	Key milestone
IBM (Condor / Heron / Flamingo)	Superconducting	1,000–4,000	Modular architecture; Heron chip targets <0.1% 2-qubit gate error. 2026 roadmap targets early error correction demonstrations.
Google (Willow)	Superconducting	105+	2024 Willow demonstrated below-threshold error correction (first time: adding more qubits reduced rather than increased error). Benchmark claim: solved in 5 min what would take classical supercomputer 10^25 years — on a specific synthetic task.
Microsoft (Azure Quantum)	Topological (Majorana)	Early demonstration	2023 topological qubit demonstration; long-term bet on hardware with inherently lower error rates. Timeline to scale is longer but potential error rate advantage is significant.
IonQ	Trapped ion	36 algorithmic qubits	Trapped ion systems have best native gate fidelity (~99.9% 2-qubit) but scale more slowly. Best error rates per qubit of any current architecture.
Quantinuum (H-series)	Trapped ion	56 qubits (H2)	H2 processor holds the highest quantum volume of any commercial system. Active pharmaceutical partnerships (AstraZeneca, Janssen) for drug discovery use cases.
D-Wave (Advantage2)	Quantum annealing	7,000+	Not general-purpose quantum computing — specialised for combinatorial optimisation. Higher qubit count but limited to annealing problems (scheduling, logistics, some optimisation). Most commercially deployed.

The critical concept here is the distinction between physical qubits and logical qubits. Physical qubits are the actual hardware components, which all have some error rate. A logical qubit is an error-corrected quantum bit implemented by encoding one logical qubit across many physical qubits, with the redundancy allowing errors to be detected and corrected. Current best estimates require approximately 1,000–10,000 physical qubits per logical qubit depending on the error correction code and the underlying hardware error rate. Almost all current quantum computers are operating in the physical qubit layer, with no or very limited error correction. Fault-tolerant quantum computing — the regime where error-corrected logical qubits enable long, reliable computation — requires hardware that does not yet exist at the necessary scale. The key milestone is the crossover point: hardware where adding more physical qubits reduces the logical error rate faster than it introduces new physical errors (below the error correction threshold). Google's 2024 Willow demonstration claimed to have crossed this threshold for the first time. If that result holds and generalises, it is a significant milestone — not a complete solution, but the first time the engineering trajectory has become definitively favourable.

The Healthcare Applications Timeline

Different healthcare applications require different levels of quantum capability. Mapping each application to the hardware maturity it requires produces a more useful and honest timeline than generic claims about quantum healthcare transformation.

NOW — 2026NISQ era · Proof of concept · Quantum-inspired classical methods

Hospital operations optimisation

D-Wave quantum annealing has been applied to staff scheduling, operating room allocation, ambulance dispatch routing, and supply chain logistics at several hospital systems. These applications use quantum annealing's natural affinity for combinatorial optimisation problems. The Cleveland Clinic and Cedars-Sinai have published results showing 15–25% efficiency gains. Classical quantum-inspired algorithms (QAOA-like methods running on classical hardware) are producing similar results and are more widely deployable — they represent the practical near-term value capture from quantum computing principles.

Genomic analysis acceleration

Quantum algorithms for sequence alignment, haplotype phasing, and variant calling have demonstrated speedups over classical methods on current NISQ hardware for small-scale problems. IBM Quantum and the Broad Institute have active collaborations. For whole-genome sequencing analysis — a task with enormous combinatorial search complexity — early quantum approaches show promise on benchmark problems, though classical hardware improvements are keeping pace. This is an area of active competition between quantum and classical approaches.

Small molecule simulation (research scale)

IBM, Google, and Quantinuum have all demonstrated quantum simulations of small molecules (H₂, LiH, BeH₂, small organic fragments) on current hardware. These demonstrations are proof-of-principle — the molecules are too small to be beyond classical methods, but they validate the algorithmic approach and benchmark hardware quality. Pharmaceutical companies are using these results to build internal quantum computing capabilities and identify which of their pipeline challenges will benefit earliest from quantum advantage.

Quantum-enhanced medical imaging (research)

Quantum machine learning algorithms for MRI reconstruction have been tested at research scale, showing potential speedups in compressed sensing reconstruction. PET image reconstruction is another candidate: the combinatorial problem of reconstructing 3D activity distribution from coincidence events maps naturally onto quantum optimisation. These remain research-stage applications — no clinical deployments in 2026.

2027–2032Early fault-tolerant · First genuine quantum advantage · Hybrid pipelines in production

Quantum-accurate drug-molecule interaction simulation

Resource estimates from IBM's Quantum Computing for Drug Discovery roadmap suggest that fault-tolerant simulation of FeMoco (the iron-molybdenum cofactor of nitrogenase — a benchmark molecule of biological relevance with ~50 active-space electrons) will require roughly 4,000 logical qubits and ~4 days of computation. This is plausibly achievable by 2030–2032 on leading hardware. The first targets will be enzyme active sites and cofactor geometries relevant to metabolic diseases and oncology — problems where quantum accuracy matters because they are dominated by electron correlation effects that classical methods approximated poorly.

Quantum-enhanced protein folding energetics

AlphaFold2 and AlphaFold3 have transformed structural biology by predicting protein folding geometry with remarkable accuracy. Their limitation is thermodynamic: they predict stable structures but not binding free energies, conformational flexibility, or allosteric dynamics with chemical accuracy. These latter properties — critical for drug design — require quantum-accurate energy calculations. Hybrid quantum-classical approaches (quantum hardware for active-site electron correlation, classical methods for the rest of the protein) are the likely near-term architecture, deployable once early logical qubits are available.

Quantum genomics for rare disease

Rare genetic diseases are caused by variants that classical GWAS methods, optimised for common variants at population scale, are poorly powered to detect. Quantum algorithms for haplotype reconstruction and rare variant burden testing in family-based cohorts are approaching classical performance on current hardware for small cohort sizes. By 2030, quantum algorithms may offer genuine advantage for the analysis of whole-genome sequencing data from rare disease families — particularly multi-gene variant interaction analyses where the combinatorial complexity of classical approaches is prohibitive.

Pharmaceutical virtual screening at quantum accuracy

Virtual screening — computationally filtering millions of candidate molecules for binding to a target protein before synthesising any — currently uses force-field or semi-empirical methods that sacrifice accuracy for speed. Quantum computers could replace the accuracy-limiting step (binding free energy calculation) with quantum-accurate calculations, dramatically reducing the false-positive rate that makes current virtual screening pipelines inefficient. AstraZeneca's quantum computing roadmap publicly targets this capability by 2030.

2033–2040Mature fault-tolerant · Industrialised quantum chemistry · Clinical impact

Full quantum drug discovery pipeline

Large pharmaceutical molecules (antibodies, oligonucleotides, complex natural product derivatives) involve hundreds to thousands of electrons in their pharmacologically relevant portions. Classical simulation of these systems is fundamentally intractable. Mature fault-tolerant quantum computers — plausibly with millions of physical qubits at sub-0.1% gate errors — would enable quantum-accurate simulation of these full systems, transforming the design of biologics and complex small molecules from primarily empirical to genuinely computational. Estimates for this capability range from 2033 to 2042 depending on hardware scaling assumptions.

Quantum-enabled personalised medicine

Personalised medicine at the quantum level means computing drug metabolism, off-target binding, and pharmacodynamics for an individual's specific metabolic enzyme variants and drug target polymorphisms — not at population average, but using quantum-accurate calculations for the patient's specific molecular variants. This vision requires both mature quantum hardware and a completed quantum-enabled drug database. It is the most transformative near-clinical application but also the furthest out.

Quantum-accelerated clinical trial design

Clinical trial design involves enormous combinatorial optimisation: patient stratification, adaptive dosing, interim analysis boundaries, biomarker selection, and multi-centre allocation problems all map onto problem classes where quantum optimisation may offer advantage. Hybrid quantum-classical approaches to trial design optimisation are plausibly near-term; full quantum advantage depends on hardware quality that is more likely in the 2030–2035 window.

The Most Important Healthcare Application: Drug Discovery

Of all the healthcare applications of quantum computing, drug discovery is both the most financially significant and the most technically credible as a near-term quantum advantage target. Understanding why helps ground the broader timeline.

Drug discovery's central computational problem is the binding affinity calculation: given a target protein and a candidate molecule, how strongly and specifically does the molecule bind to the protein's active site? This determines efficacy. The precision required for useful predictions — accurate to within ~1 kcal/mol — requires capturing electron correlation effects that classical quantum chemistry approximates poorly for large systems. The state-of-the-art classical method (CCSD(T) coupled cluster) is only tractable for ~50 heavy atoms on today's supercomputers. Most drug molecules of clinical interest have 50–100+ heavy atoms in their pharmacophore.

The current drug development process has a ~90% clinical failure rate and an average cost per approved drug of approximately $2.6 billion, driven primarily by compounds that show computational promise but fail in expensive late-stage trials due to binding affinity prediction errors, off-target effects, and metabolic liability predictions that classical methods got wrong. Even a partial improvement in binding affinity prediction accuracy — reducing the late-stage clinical failure rate from 90% to 80% — would generate enormous economic value, which is why pharmaceutical investment in quantum computing is robust despite the long timeline.

The variational quantum eigensolver (VQE) and quantum phase estimation (QPE) are the two main algorithmic approaches being developed for molecular simulation on quantum hardware. VQE is better suited to NISQ-era machines (it is more noise-tolerant) but gives only approximate energies. QPE gives exact ground-state energies but requires deeply error-corrected logical qubits. The trajectory is: VQE provides useful approximate calculations on improving NISQ hardware through the late 2020s; early fault-tolerant machines enable QPE on small drug-relevant molecules in the early 2030s; mature fault-tolerant machines enable QPE on large pharmaceutically relevant systems later in the 2030s.

Barriers to Clinical Deployment

Understanding the barriers separating current quantum research from clinical impact helps calibrate realistic expectations.

Error rates

Current best 2-qubit gate error rates are approximately 0.1–0.3% on superconducting processors and ~0.1% on trapped ion systems. Fault-tolerant logical qubit operation requires physical error rates below ~0.1% for most error correction codes, with many thousands of physical qubits per logical qubit. The crossover point where logical qubits become practical is the central technical challenge of the field. Most estimates put practical fault-tolerant operation at 10–15 years from now.

Coherence time

Qubits must maintain their quantum state long enough to complete a computation before decoherence destroys the quantum information. Current superconducting qubits have coherence times of 100–500 microseconds — sufficient for short circuits but not the millions of gate operations that fault-tolerant molecular simulation requires. Trapped ion and photonic qubits have longer coherence times but slower gate speeds. Extending coherence while maintaining gate speed and scaling qubit count is a three-dimensional engineering problem with no single solution.

Cryogenic infrastructure

Superconducting quantum processors operate at 10–20 millikelvin — colder than interstellar space and requiring dilution refrigerators the size of a wardrobe. This infrastructure is expensive, power-intensive, and incompatible with clinical deployment at point-of-care. Quantum computing in healthcare will be a cloud-accessed service, not a bedside technology. This is fine for drug discovery (which is inherently centralised) but limits applications requiring real-time local computation. Trapped ion and photonic systems may ultimately allow smaller form factors, but this is years from practical realisation.

Algorithm development

The hardware timeline gets most of the attention, but algorithm development is an equally important constraint. For most healthcare applications, the quantum algorithms that would actually deliver advantage are still being developed. VQE and QPE have known scaling properties; what is less clear is how to input-encode real biological problems efficiently, how to handle the classical pre- and post-processing that surrounds the quantum computation, and how to validate quantum results against the classical approximate solutions they are meant to replace. These are active research problems across dozens of academic groups and industry labs.

Regulatory pathways

Quantum-computed drug properties used in clinical decision-making or regulatory submissions will require validation frameworks that do not yet exist. The FDA's current guidance on computational methods was written for classical force-field and AI/ML approaches. Quantum-computed binding affinities will require a new validation paradigm — establishing how well quantum predictions correlate with experimental measurements across relevant chemical spaces. This regulatory infrastructure development will likely lag behind the hardware by 3–5 years.

Quantum Computing vs. Quantum Biology: An Important Distinction

A frequent source of confusion in healthcare discussions is the conflation of quantum computing (engineering machines that exploit quantum mechanics) with quantum biology (the study of quantum mechanical phenomena in living systems). They are related in the sense that quantum computing is one of the best tools for studying quantum biology — but they are distinct fields with different timelines and different implications for clinical practice.

Quantum biology is not speculative. Quantum coherence in photosynthetic energy transfer, demonstrated by Graham Fleming's group in 2007, showed that plants exploit quantum superposition to efficiently route excitation energy to reaction centres at near-100% efficiency — a feat impossible by classical thermal diffusion. Quantum tunnelling in enzyme-catalysed hydrogen transfer has been demonstrated in alcohol dehydrogenase, aromatic amine dehydrogenase, and multiple other enzymes — and explains reaction rates 10¹⁰–10²⁰ times faster than classical transition-state theory predicts. The radical pair mechanism in flavoproteins provides a quantum-mechanical explanation for magnetoreception in birds and potentially in humans. These are established biophysics, published in Nature, Science, and the Proceedings of the National Academy of Sciences.

The frontier question — and the one most relevant to the QuanMed AI framework — is how far these molecular-scale quantum effects propagate into macroscopic physiology and whether disrupting them (through artificial electromagnetic fields, toxic exposures, or metabolic dysfunction) contributes to the chronic disease burden of modern industrial populations. This is a live research question with suggestive but not yet definitive evidence. Quantum computing, as it matures, will be a primary tool for investigating it — because only quantum-accurate molecular simulations can test whether specific biological processes exploit quantum effects in ways that are metabolically significant. The two fields are ultimately converging.

Key Players and Their Healthcare Strategies

IBM Quantum

IBM has the broadest pharmaceutical partnership portfolio, with Pfizer, ExxonMobil, Boeing, and multiple biotech companies. Their Healthcare and Life Sciences focus explicitly targets drug discovery simulation, genomic optimisation, and clinical trial design. IBM's annual quantum roadmap — updated each year and generally considered the most transparent in the industry — provides the most useful public benchmark for tracking hardware progress. Their 2025–2028 roadmap targets the first demonstrations of quantum advantage in industrially relevant molecular simulation tasks.

Google Quantum AI

Google's 2024 Willow chip achieved the first below-threshold error correction result — meaning adding more physical qubits improved logical error rates, the critical proof that error correction can work. Google's healthcare focus is primarily through its broader AlphaFold / DeepMind collaboration, with quantum computing positioned as the longer-term enabler of quantum-accurate protein simulation beyond AlphaFold's current capabilities. Their quantum chemistry roadmap targets simulation of molecules with 100+ active electrons by 2030.

Quantinuum

The Honeywell–Cambridge Quantum merger created Quantinuum with the highest quantum volume (a composite measure of qubit count, connectivity, and gate fidelity) of any commercial system. Their System Model H2 has been used by AstraZeneca for drug-molecule binding calculations and by Janssen (J&J) for protein-ligand optimisation. Quantinuum publishes the most detailed pharmaceutical use case results of any hardware company — making them a useful reference point for what is actually achievable on current hardware vs. what requires future improvements.

Pharmaceutical adopters

AstraZeneca, Boehringer Ingelheim, Roche, Merck KGaA, and Biogen have the most developed internal quantum computing programmes among major pharmaceutical companies. Boehringer Ingelheim's partnership with Google Quantum AI is focused on use of quantum computers to calculate molecular properties relevant to their respiratory and cardiometabolic pipelines. Roche is investigating quantum algorithms for drug-resistant bacterial enzyme simulation. These are substantial research investments — not token announcements — and the companies involved are tracking hardware progress carefully against internal estimates of when quantum advantage crosses into their drug discovery workflows.

A Note on Quantum Hype

Quantum computing has attracted a well-documented hype cycle. Understanding its contours helps calibrate what to believe. The most common oversimplifications to watch for:

•Qubit count as the primary metric. A machine with 1,000 noisy, poorly connected physical qubits is less useful than one with 50 high-fidelity, fully connected qubits for most algorithms. IBM's qubit count race of 2021–2022 produced impressive numbers but limited algorithmic value; they have since pivoted to emphasising quality metrics.

•"Quantum supremacy" = universal quantum advantage. Google's 2019 supremacy demonstration and subsequent results prove quantum machines can do something specific faster than classical machines. They do not prove quantum advantage on any practically useful task. The benchmarks used (sampling random circuit outputs) were chosen because they are hard for classical computers, not because they are useful.

•Near-term clinical applications. Any announcement claiming quantum computing will be used in clinical diagnostics, patient monitoring, or bedside decision support within 5 years should be read critically. The cryogenic infrastructure, error rates, and algorithm development required make clinical-setting deployment implausible before 2035 at the earliest.

•Equating quantum-inspired with quantum. Many commercial products marketed as 'quantum' optimisation tools are running classical algorithms inspired by quantum approaches (simulated annealing, tensor networks, quantum-inspired optimisation). These can be genuinely useful — but they do not require quantum hardware and their performance advantages have no dependence on quantum mechanics.

The honest position: quantum computing's potential impact on drug discovery is not hype — it is grounded in fundamental physics and has attracted serious long-term investment from both pharmaceutical companies and national governments (the US National Quantum Initiative, EU Quantum Flagship, UK National Quantum Computing Centre). The timeline for that impact is longer than press releases typically state. The field is progressing measurably and faster than many 2015-era sceptics expected. Following the published hardware roadmaps from IBM, Google, and Quantinuum — and the pharmaceutical partnership announcements that test real use cases on real hardware — is the best way to track it without being misled by either excessive optimism or excessive scepticism.

Explore the QuanMed AI Platform

QuanBot AI MyDeMed Portal AI Models About QuanMed

Jan 15, 2026

Quantum Computing in Healthcare: Timeline & Reality Check